Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GLP-1 Agonists Show Promise in Treating Substance Use Disorders Nov 7, 2025 5 min read Updated: Dec 17, 2025 In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditionssuch as semaglutide and liraglutideare showing promise in treating substance use disorders (SUDs)
Track your side effects and appetite patterns in a simple journal across two weeks to identify your personal response pattern
The upper section relaxes to hold what you've eaten while the lower muscles squeeze it along
BPC-157: Proposed to treat ulcerative colitis TB-500: Proposed for wound healing KPV: Proposed for wound healing and inflammatory conditions MOTS-c: Proposed to treat obesity and osteoporosis Semax: Proposed to treat cerebral ischemia (a shortage of blood flow and oxygen to the brain), migraine and trigeminal neuralgia (a chronic pain condition in the face) Epitalon: Proposed to treat insomnia While some peptide experts celebrate this as one step closer to access to life-improving drugs, others claim there isnt enough data on safety and efficacy
This continuous monitoring can lead to better disease management and more timely adjustments in GLP-1 therapy
US$ 28.74
US$ 20.43
US$ 27.45
US$ 24.85
